A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk irrespective of conventional risk factors. The role of gut-liver interaction is implicated in its development. We investigated the effects of VSL#3(®) probiotic supplementation on biomarkers of car...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Pui Lin, Laight, David, Aspinall, Richard J., Higginson, Antony, Cummings, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015038/
https://www.ncbi.nlm.nih.gov/pubmed/33794784
http://dx.doi.org/10.1186/s12876-021-01660-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015038/
https://www.ncbi.nlm.nih.gov/pubmed/33794784
http://dx.doi.org/10.1186/s12876-021-01660-5

Ejemplares similares